Evidence map›Paper›PMID 34736896›Full record

ArticleThe Journal of biological chemistry2021

β-synuclein potentiates synaptic vesicle dopamine uptake and rescues dopaminergic neurons from MPTP-induced death in the absence of other synucleins.

Natalia Ninkina, Steven J Millership, Owen M Peters, Natalie Connor-Robson, Kirill Chaprov, Arthur T Kopylov, Alex Montoya, Holger Kramer, Dominic J Withers, Vladimir L Buchman

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
1.4field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Fluid markers of synapse degeneration in synucleinopathies.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 2 countries.

Natalia NinkinaSchool of Biosciences, Cardiff University, Cardiff, United Kingdom; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russian Federation.
Steven J MillershipSchool of Biosciences, Cardiff University, Cardiff, United Kingdom; Metabolic Signalling, MRC London Institute of Medical Sciences, London, United Kingdom; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom.
Owen M PetersSchool of Biosciences, Cardiff University, Cardiff, United Kingdom.
Natalie Connor-RobsonSchool of Biosciences, Cardiff University, Cardiff, United Kingdom.
Kirill ChaprovSchool of Biosciences, Cardiff University, Cardiff, United Kingdom; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russian Federation.
Arthur T KopylovDepartment of Proteomic Research and Mass Spectrometry, Institute of Biomedical Chemistry, Moscow, Russian Federation.
Alex MontoyaMetabolic Signalling, MRC London Institute of Medical Sciences, London, United Kingdom.
Holger KramerMetabolic Signalling, MRC London Institute of Medical Sciences, London, United Kingdom.
Dominic J WithersMetabolic Signalling, MRC London Institute of Medical Sciences, London, United Kingdom; Institute of Clinical Sciences, Faculty of Medicine, Imperial College London, London, United Kingdom.
Vladimir L BuchmanSchool of Biosciences, Cardiff University, Cardiff, United Kingdom; Institute of Physiologically Active Compounds, Russian Academy of Sciences, Chernogolovka, Russian Federation. Electronic address: buchmanvl@cf.ac.uk.
MRC London Institute of Medical Sciences · GBInstitute of Physiologically Active Compounds · RUCardiff University · GBInstitute of Biomedical Chemistry · RU

Funding

ENHANCED COMPREHENSIVE HIV PREVENTION PLANNING AND IMPLEMENTATION FOR THE BALTIMOU65PS003619 · PS · MARYLAND STATE DEPARTMENT OF HEALTH · PI BLYTHE, DAVID · 2011 to 2012
$2.0M
Medical Research Council MC-A654-5QB40Medical Research Council MC_U120097114NCHHSTP CDC HHS U65 PS003619Wellcome TrustWellcome Trust 075615/Z/04/ZWellcome Trust PS3619_WREC
6 · The paper itself

Abstract

Synucleins, a family of three proteins highly expressed in neurons, are predominantly known for the direct involvement of α-synuclein in the etiology and pathogenesis of Parkinson's and certain other neurodegenerative diseases, but their precise physiological functions are still not fully understood. Previous studies have demonstrated the importance of α-synuclein as a modulator of various mechanisms implicated in chemical neurotransmission, but information concerning the involvement of other synuclein family members, β-synuclein and γ-synuclein, in molecular processes within presynaptic terminals is limited. Here, we demonstrated that the vesicular monoamine transporter 2-dependent dopamine uptake by synaptic vesicles isolated from the striatum of mice lacking β-synuclein is significantly reduced. Reciprocally, reintroduction, either in vivo or in vitro, of β-synuclein but not α-synuclein or γ-synuclein improves uptake by triple α/β/γ-synuclein-deficient striatal vesicles. We also showed that the resistance of dopaminergic neurons of the substantia nigra pars compacta to subchronic administration of the Parkinson's disease-inducing prodrug 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine depends on the presence of β-synuclein but only when one or both other synucleins are absent. Furthermore, proteomic analysis of synuclein-deficient synaptic vesicles versus those containing only β-synuclein revealed differences in their protein compositions. We suggest that the observed potentiation of dopamine uptake by β-synuclein might be caused by different protein architecture of the synaptic vesicles. It is also feasible that such structural changes improve synaptic vesicle sequestration of 1-methyl-4-phenylpyridinium, a toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, which would explain why dopaminergic neurons expressing β-synuclein and lacking α-synuclein and/or γ-synuclein are resistant to this neurotoxin.

Indexed as

1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAnimalsbeta-SynucleinCell DeathDopamineDopaminergic NeuronsMiceMice, KnockoutSynaptic Vesicles1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridinebeta-SynucleinDopamineSncb protein, mousedopaminedopaminergic neuronsMPTP toxicityneurodegenerative diseaseneurotransmitter vesicular uptakeParkinson's diseasesynapsesynucleintransgenic micevesicles

Identifiers

PMID34736896
PMCPMC8633583
OpenAlexW3209827614

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.